Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB

European Respiratory Journal

Volumn 47, Issue 4, 2016, Pages 1235-1243

  Tiberi, Simon ^a   Payen, Marie Christine ^b   Sotgiu, Giovanni ^c   D'Ambrosio, Lia ^d,e   Guizado, Valentina Alarcon ^f   Alffenaar, Jan Willem ^g   Arbex, Marcos Abdo ^h,i   Caminero, Jose A ^j,k   Centis, Rosella ^d   De Lorenzo, Saverio ^l   Gaga, Mina ^m   Gualano, Gina ⁿ   Arias, Aurora Jazmín Roby ^o   Scardigli, Anna ^k   Skrahina, Alena ^p   Solovic, Ivan ^q   Sulis, Giorgia ^r   Tadolini, Marina ^s   Akkerman, Onno W ^g   Arrascue, Edith Alarcon ^k,t   Aleska, Alena ^u   Avchinko, Vera ^p   Bonini, Eduardo Henrique ^h,i   Marín, Félix Antonio Chong ^o   López, Lorena Collahuazo ^o   De Vries, Gerard ^v   Dore, Simone ^c   Kunst, Heinke ^w   Matteelli, Alberto ^r   Moschos, Charalampos ^m   Palmieri, Fabrizio ⁿ   Papavasileiou, Apostolos ^m   Spanevello, Antonio ^d,x   Vasquez, Dante Vargas ^y   Viggiani, Pietro ^l   White, Veronica ^a   Zumla, Alimuddin ^z   Migliori, Giovanni Battista ^d   more..

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF SASSARI   (Italy)

^d IRCCS   (Italy)

^e Public Health Consulting Group SAGL   (Switzerland)

^f MINISTERIO DE SALUD   (Peru)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h University Center of Araraquara   (Brazil)

ⁱ Hospital Nestor Goulart Reis   (Brazil)

^j HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^k INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^l Reference Hospital for MDR and HIV TB   (Italy)

^m SOTIRIA GENERAL HOSPITAL   (Greece)

ⁿ NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^o National Tuberculosis Control Programme   (Ecuador)

^p Republican Scientific and Practical Center for Pulmonology and Tuberculosis   (Belarus)

^q National Institute for TB Lung Diseases and Thoracic Surgery Vysne Hagy   (Slovakia)

^r UNIVERSITY OF BRESCIA   (Italy)

^s UNIVERSITY OF BOLOGNA   (Italy)

^t International Union Against Tuberculosis and Lung Disease (The Union)   (Peru)

^u GRODNO STATE MEDICAL UNIVERSITY   (Belarus)

^v KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^w QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^x UNIVERSITY OF INSUBRIA   (Italy)

^y Hospital Nacional Hipólito Unanue   (Peru)

^z UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; CLAVULANIC ACID; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIENAMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ANEMIA; ANTIBIOTIC RESISTANCE; ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPUTUM CULTURE; SPUTUM SMEAR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; CLAVULANIC ACID; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; THIENAMYCINS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84964054940     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02146-2015     Document Type: Article

References (46)

1. World Health Organization. Global Tuberculosis Report 2015. Geneva, World Health Organization, 2015.
2. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
3. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
4. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
5. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-115.
6. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: A systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
7. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
8. Migliori GB, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: E070517.1.
9. Caminero JA, Scardigli A. Classification of antituberculosis drugs: A new proposal based on the most recent evidence. Eur Respir J 2015; 46: 887-893.
10. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015; 45: 25-29.
11. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and MDR-TB: A systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402.
12. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
13. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Eur Respir J 2013; 41: 1393-1400.
14. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
15. Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564-574.
16. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
17. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
18. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
19. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-985.
20. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
21. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. Eur Respir J 2016; 47: 664-667.
22. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in MDR-TB. Eur Respir J 2009; 34: 387-393.
23. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2011; 38: 730-733.
24. De Lorenzo S, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. Eur Respir J 2012; 39: 770-772.
25. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
26. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
27. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
28. Sotgiu G, Centis R, D'Ambrosio L, et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J 2015; 45: 287-289.
29. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
30. Payen MC, De Wit S, Martin C, et al. Clinical use of meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 558-560.
31. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Ertapenem in the treatment of MDR-TB: first clinical experience. Eur Respir J 2016; 47: 333-336.
32. van Rijn SP, van Altena R, Akkerman OW, et al. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. Eur Respir J 2016; 47: 1229-1234.
33. Chambers HF, Turner J, Schecter GF, et al. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005; 49: 2816-2282.
34. Arbex MA, Ribeiro de Siqueira H, D'Ambrosio L, et al. The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: A report of three cases. J Bras Pneumol 2015; 41: 554-559.
35. Yew WW, Wong CF, Lee J, et al. Do beta-lactam-beta-lactmase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tubercle Lung Dis 1995; 78: 90-92.
36. Hugonnet JE, Blanchard JS. Irreversible inhibition of Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 2007; 46: 11198-12004.
37. Hugonnet JE, Tremblay LW, Boshoff HI, et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-1218.
38. Payen M, Martin C, Antoine-Moussiaux T, et al. Four cases of XDR-TB treated with meropenem-clavulanate. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2010. Abstract L1-517. www. abstractsonline.com/Plan/ViewAbstract.aspx?sKey=7189a738-03a3-41e0-8ee5-cf36269b5766&cKey=aceae86c-c8ae-4d8e-968e-d2dd95abed53&mKey=%7b93AEED6A-54D4-4EF6-99BD-A9B3CE9FACD9%7d Date last accessed: February 23, 2016.
39. Veziris N, Truffot C, Mainardi J-L, et al. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother 2011; 55: 2597-2600.
40. Palmero D, Montaner PG, Cufré M, et al. Primera serie de pacientes con TB-XDR y pre-XDR tratados con esquemas que incluyeron meropenem-clavulanato en Argentina. [First series of patients with XDR and Pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina.] Arch Bronconeumol 2015; 51: e49-e52.
41. Winters N, Butler-Laporte G, Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J 2015; 46: 1461-1470.
42. Alsaad N, Wilffert B, van Altena R, et al. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 2014; 43: 884-897.
43. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 504-512.
44. Krieger D, Vesenbeckh S, Schönfeld N, et al. Mefloquine as a potential drug against multidrug-resistant tuberculosis. Eur Respir J 2015; 46: 1503-1505.
45. Matteelli A, D'Ambrosio L, Centis R, et al. Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis 2015; 15: 1131-1132.
46. Lonnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.